AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dare Bioscience, Inc. Director's Dealing 2015

Mar 25, 2015

34825_dirs_2015-03-25_95610ba7-d6ff-49b2-a8dd-087544ebe833.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cerulean Pharma Inc. (CERU)
CIK: 0001401914
Period of Report: 2015-03-23

Reporting Person: GUIFFRE CHRISTOPHERD T (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-03-23	Stock Option (right to buy)	$9.84	A	407520	Acquired	2025-03-22	Common Stock (407520)	Direct

Footnotes

F1: This option was granted on March 23, 2015. The option vests as to 2.08333% of the underlying shares monthly through and including March 23, 2019.